Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen

被引：81
作者：
Elsaesser-Beile, U. [1 ]
Buehler, P. [1 ]
Wolf, P. [1 ]
机构：
[1] Univ Freiburg, Dept Urol, D-79106 Freiburg, Germany
来源：
CURRENT DRUG TARGETS | 2009年 / 10卷 / 02期
关键词：
Prostate specific membrane antigen; prostate cancer; immunotherapy; drug targeting; radiotherapy; gene therapy; MONOCLONAL-ANTIBODY J591; PHASE-I TRIAL; GLUTAMATE-CARBOXYPEPTIDASE-II; POSITRON-EMISSION-TOMOGRAPHY; ANDROGEN-DEPRIVATION THERAPY; MALIGNANT HUMAN TISSUES; LYMPH-NODE METASTASES; CARCINOMA CELL-LINE; EXTRACELLULAR DOMAIN; DENDRITIC CELLS;
D O I：
10.2174/138945009787354601
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and first-generation products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.
引用
收藏
页码：118 / 125
页数：8
相关论文
共 99 条
[41]  
Lodge PA, 2000, CANCER RES, V60, P829
[42]  
LOPES AD, 1990, CANCER RES, V50, P6423
[43]  
Lupold SE, 2002, CANCER RES, V62, P4029
[44]   Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen [J].
Ma, DS ;
Hopf, CE ;
Malewicz, AD ;
Donovan, GP ;
Senter, PD ;
Goeckeler, WF ;
Maddon, PJ ;
Olson, WC .
CLINICAL CANCER RESEARCH, 2006, 12 (08) :2591-2596
[45]   Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy [J].
Ma, QZ ;
Safar, M ;
Holmes, E ;
Wang, YW ;
Boynton, AL ;
Junghans, RP .
PROSTATE, 2004, 61 (01) :12-25
[46]   Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor [J].
Maher, J ;
Brentjens, RJ ;
Gunset, G ;
Rivière, I ;
Sadelain, M .
NATURE BIOTECHNOLOGY, 2002, 20 (01) :70-75
[47]  
McDevitt MR, 2000, CANCER RES, V60, P6095
[48]   Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer [J].
Mesters, JR ;
Barinka, C ;
Li, WX ;
Tsukamoto, T ;
Majer, P ;
Slusher, BS ;
Konvalinka, J ;
Hilgenfeld, R .
EMBO JOURNAL, 2006, 25 (06) :1375-1384
[49]   Use of methotrexate-based peptide substrates to characterize the substrate specificity of Prostate-Specific Membrane Antigen (PSMA) [J].
Mhaka, A ;
Gady, AM ;
Rosen, DM ;
Lo, KM ;
Gillies, SD ;
Denmeade, SR .
CANCER BIOLOGY & THERAPY, 2004, 3 (06) :551-558
[50]  
Mhaka Annastasiah, 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P725
12345678910